Lineage Cell Therapeutics (LCTX) Capital Leases (2015 - 2026)

Lineage Cell Therapeutics' Capital Leases history runs 12 years deep, the most recent figure standing at $22000.0 for Q1 2026.

• In Q1 2026, Capital Leases fell 56.86% year-over-year to $22000.0; the TTM figure through Mar 2026 stood at $22000.0 (down 56.86% YoY), while the FY2025 annual figure was $32000.0, down 52.24% from the prior year.
• Capital Leases for Q1 2026 stood at $22000.0, down from $32000.0 in the prior quarter.
• The five-year high for Capital Leases was $133000.0 in Q1 2023, with the low at $16000.0 in Q3 2022.
• The 5-year median for Capital Leases is $67000.0 (2024), against an average of $62705.9.
• The sharpest annual moves came in 2023 and 2026: Capital Leases soared 506.25% in 2023, then slumped 56.86% in 2026.
• Lineage Cell Therapeutics' Capital Leases stood at $84000.0 in 2022, then climbed by 8.33% to $91000.0 in 2023, then retreated by 26.37% to $67000.0 in 2024, then tumbled by 52.24% to $32000.0 in 2025, then plunged by 31.25% to $22000.0 in 2026.
• Business Quant data shows LCTX's Capital Leases at $22000.0 in Q1 2026, $32000.0 in Q4 2025, and $40000.0 in Q3 2025.